Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2013 3
2014 4
2015 1
2016 2
2017 4
2018 5
2019 6
2020 4
2021 6
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Free article. Clinical Trial.
Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, Jacobs I, Lawo JP, Glassman F, Akama H, Hide M, Ohsawa I. Fukuda T, et al. Among authors: lawo jp. Allergol Int. 2023 Jul;72(3):451-457. doi: 10.1016/j.alit.2023.02.002. Epub 2023 Feb 28. Allergol Int. 2023. PMID: 36858856 Free article. Clinical Trial.
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
Tortorici MA, Yuraszeck T, Cornblath D, Bril V, Hartung HP, Sobue G, Lewis RA, Merkies ISJ, Lawo JP, Praus M, Durn BL, Mielke O, Ma X, Jauslin P, Pfister M, van Schaik IN; PATH study group. Tortorici MA, et al. Among authors: lawo jp. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):839-850. doi: 10.1002/psp4.12647. Epub 2021 Aug 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34085779 Free PMC article.
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králíčková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL; COMPACT Investigators. Longhurst H, et al. Among authors: lawo jp. N Engl J Med. 2017 Mar 23;376(12):1131-1140. doi: 10.1056/NEJMoa1613627. N Engl J Med. 2017. PMID: 28328347 Free article. Clinical Trial.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. Lumry WR, et al. Among authors: lawo jp. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31. J Allergy Clin Immunol Pract. 2018. PMID: 29391286 Free article. Clinical Trial.
33 results